Hyperlipidemia
Episodes 1-16 of 23
Christie M. Ballantyne, MD, FACP, FACC
Daniel Gaudet, MD, PhD
Pam R. Taub, MD, FACC, FASPC
P. Gabriel Steg, MD
Erik Stroes, MD, PhD
P. Gabriel Steg, MD
Pam R. Taub, MD, FACC, FASPC
Erik Stroes, MD, PhD
Lale Tokgözoğlu, MD
- MinuteCE®
Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi
1.00 program creditErin D. Michos, MD, MHS, FACC, FAHA, FASE
Fabrice Martens, MD, PhD, FESC
Prof. Kausik Ray, MBChB, MD, MPhil
Lale Tokgözoğlu, MD
Fabrice Martens, MD, PhD, FESC
Erin D. Michos, MD, MHS, FACC, FAHA, FASE
- MinuteCE®
The evolving need and challenges to reach LDL-c targets in high-risk patients
1.00 program creditProf. Kausik Ray, MBChB, MD, MPhil
Stephen Nicholls, FRACP, FACC, FESC, FAHA
John Kastelein, MD, PhD
Roxana Mehran, MD
Stephen Nicholls, FRACP, FACC, FESC, FAHA
- MinuteCE®
New insights on CETP inhibition from genetic research and clinical trials
1.00 program creditJohn Kastelein, MD, PhD
Roxana Mehran, MD
Lale Tokgözoğlu, MD
- Prev
- Next